123 related articles for article (PubMed ID: 10566061)
1. MDL 100240.
Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
[No Abstract] [Full Text] [Related]
2. Sampatrilat. UK 81252.
Drugs R D; 1999 Apr; 1(4):352-3. PubMed ID: 10566063
[No Abstract] [Full Text] [Related]
3. Fasidotril. Aladotril, alatriopril, BP 1137.
Drugs R D; 1999 Apr; 1(4):346-7. PubMed ID: 10566060
[No Abstract] [Full Text] [Related]
4. Omapatrilat.
Drugs R D; 1999 Apr; 1(4):350-1. PubMed ID: 10566062
[No Abstract] [Full Text] [Related]
5. Ecadotril. (S)-acetorphan, sinorphan.
Drugs R D; 1999 Apr; 1(4):343-5. PubMed ID: 10566059
[No Abstract] [Full Text] [Related]
6. SCH 42495.
Drugs R D; 1999 Apr; 1(4):354-6. PubMed ID: 10566064
[No Abstract] [Full Text] [Related]
7. Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100240.
Rossi GP
Cardiovasc Drug Rev; 2003; 21(1):51-66. PubMed ID: 12595917
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
French JF; Anderson BA; Downs TR; Dage RC
J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
[TBL] [Abstract][Full Text] [Related]
9. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
Heinzl S
Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
[No Abstract] [Full Text] [Related]
10. Candoxatrilat. UK 73967.
Drugs R D; 1999 Apr; 1(4):341-2. PubMed ID: 10566058
[No Abstract] [Full Text] [Related]
11. Endopeptidase inhibitors. Summary and table.
Coleman SG; Duff R
Drugs R D; 1999 Apr; 1(4):339-40. PubMed ID: 10566057
[No Abstract] [Full Text] [Related]
12. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
[TBL] [Abstract][Full Text] [Related]
13. Vasopeptidase inhibitors--concepts and evidence.
Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF
Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147
[No Abstract] [Full Text] [Related]
14. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Trippodo NC; Robl JA; Asaad MM; Bird JE; Panchal BC; Schaeffer TR; Fox M; Giancarli MR; Cheung HS
J Pharmacol Exp Ther; 1995 Nov; 275(2):745-52. PubMed ID: 7473162
[TBL] [Abstract][Full Text] [Related]
15. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.
Balfour JA; Goa KL
Drugs; 1991 Sep; 42(3):511-39. PubMed ID: 1720384
[TBL] [Abstract][Full Text] [Related]
16. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
[TBL] [Abstract][Full Text] [Related]
17. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1694-701. PubMed ID: 9422816
[TBL] [Abstract][Full Text] [Related]
19. [Omapatrilat for treatment of heart failure].
Yamazaki T
Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
[No Abstract] [Full Text] [Related]
20. Three new ACE inhibitors for hypertension.
Med Lett Drugs Ther; 1991 Sep; 33(852):83-4. PubMed ID: 1831531
[No Abstract] [Full Text] [Related]
[Next] [New Search]
